India, April 8 -- Lyka Labs Limited is proud to announce the grant of an Indian Patent for its novel formulation, Pregabalin Gel 8%, with patent protection extending until 2043. This achievement marks a significant step forward in Lyka's commitment to pharmaceutical innovation and its expertise in advanced topical drug delivery systems.
Pregabalin Gel 8% is a pioneering topical solution developed for the management of diabetic neuropathic pain. The product received regulatory approval from the Central Drugs Standard Control Organization (CDSCO) in October 2024 and was subsequently launched in December 2024 through Torrent Pharmaceuticals, Intas Pharmaceuticals, and Zuventus Healthcare under a P2P (Product-to-Product) licensing agreement wi...